A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
in respect of the meridians (经络辩证; jīngluò biàn zhèng) in respect of qi (气血辩证,; qì xuè biàn zhèng) in respect of xuè (气血辩证; qì xuè biàn zhèng) in respect of the body fluids (津液辩证; jīnyè biàn zhèng) in respect of the zàng-fǔ (脏腑辩证; zàngfǔ biàn zhèng) – very similar to this, though less specific, is disharmony pattern description in terms of the Five Elements [五行辩证; wǔ xíng biàn zhèng]) There are also three special pattern diagnosis systems used in case of febrile and infectious diseases only ("Six Channel system" or "six division pattern" [六经辩证; liù jīng biàn zhèng]; "Wei Qi Ying Xue system" or "four division pattern" [卫气营血辩证; weì qì yíng xuè biàn zhèng]; "San Jiao system" or "three burners pattern" [三焦辩证; sānjiaō biàn zhèng]).
== External links == Genome-based Peptide Fingerprint Scanning (GFS) Documentation Archived 27 September 2013 at the Wayback Machine Facebook link to "Genome-based Peptide Fingerprint Scanning" Explanation of MS/MS in relation to MASCOT
All vertebrates have a similar basic body plan and at some point in their lives, mostly in the embryonic stage, share the major chordate characteristics: a stiffening rod, the notochord; a dorsal hollow tube of nervous material, the neural tube; pharyngeal arches; and a tail posterior to the anus. The spinal cord is protected by the vertebral column and is above the notochord, and the gastrointestinal tract is below it. Nervous tissue is derived from the ectoderm, connective tissues are derived from mesoderm, and gut is derived from the endoderm. At the posterior end is a tail which continues the spinal cord and vertebrae but not the gut. The mouth is found at the anterior end of the animal, and the anus at the base of the tail. The defining characteristic of a vertebrate is the vertebral column, formed in the development of the segmented series of vertebrae. In most vertebrates the notochord becomes the nucleus pulposus of the intervertebral discs. However, a few vertebrates, such as the sturgeon and the coelacanth, retain the notochord into adulthood. Jawed vertebrates are typified by paired appendages, fins or legs, which may be secondarily lost. The limbs of vertebrates are considered to be homologous because the same underlying skeletal structure was inherited from their last common ancestor. This is one of the arguments put forward by Charles Darwin to support his theory of evolution.
SRIs like citalopram and paroxetine, as well as the serotonin 5-HT2A receptor antagonist ketanserin, have been found to partially block the increases in heart rate and blood pressure with MDMA. It is notable in this regard that serotonergic psychedelics such as psilocybin, which act as serotonin 5-HT2A receptor agonists, likewise have sympathomimetic effects. The NRI reboxetine and the serotonin–norepinephrine reuptake inhibitor (SNRI) duloxetine block MDMA-induced increases in heart rate and blood pressure. Conversely, bupropion, a norepinephrine–dopamine reuptake inhibitor (NDRI) with only weak dopaminergic activity, reduced MDMA-induced heart rate and circulating norepinephrine increases but did not affect MDMA-induced blood pressure increases. On the other hand, the robust NDRI methylphenidate, which has sympathomimetic effects of its own, has been found to augment the cardiovascular effects and increases in circulating norepinephrine and epinephrine levels induced by MDMA. The non-selective beta blocker pindolol blocked MDMA-induced increases in heart rate but not blood pressure. The α2-adrenergic receptor agonist clonidine did not affect the cardiovascular effects of MDMA, though it reduced blood pressure. The α1-adrenergic receptor antagonists doxazosin and prazosin blocked or reduced MDMA-induced blood pressure increases but augmented MDMA-induced heart rate and cardiac output increases. The dual α1- and β-adrenergic receptor blocker carvedilol reduced MDMA-induced heart rate and blood pressure increases.
=== Homo erectus === At the beginning of the Paleolithic, hominins were found primarily in eastern Africa, east of the Great Rift Valley. Most known hominin fossils dating earlier than one million years before present are found in this area, particularly in Kenya, Tanzania, and Ethiopia. By c. 2,000,000 – c. 1,500,000 BP, groups of hominins began leaving Africa, settling southern Europe and Asia. The South Caucasus was occupied by c. 1,700,000 BP, and northern China was reached by c. 1,660,000 BP. By the end of the Lower Paleolithic, members of the hominin family were living in what is now China, western Indonesia, and, in Europe, around the Mediterranean and as far north as England, France, southern Germany, and Bulgaria. Their further northward expansion may have been limited by the lack of control of fire: studies of cave settlements in Europe indicate no regular use of fire prior to c. 400,000 – c. 300,000 BP. East Asian fossils from this period are typically placed in the genus Homo erectus. Very little fossil evidence is available at known Lower Paleolithic sites in Europe, but it is believed that hominins who inhabited these sites were likewise Homo erectus. There is no evidence of hominins in America, Australia, or almost anywhere in Oceania during this time period. Fates of these early colonists, and their relationships to modern humans, are still subject to debate. According to current archaeological and genetic models, there were at least two notable expansion events subsequent to peopling of Eurasia c. 2,000,000 – c. 1,500,000 BP.
Sources: en.wikipedia.org
==== Riots ==== Heseltine became the troubleshooter to deal with the explosion of violence in Britain's inner cities in the aftermath of the Brixton and Toxteth riots of 1981. Unemployment had reached 20% in Liverpool as a whole, but 60% among young black residents in Toxteth. Tear gas had had to be used, and the Cabinet contemplated deploying the Army. A few weeks before the riots, a Cabinet thinktank had proposed that the area be left to go into "managed decline". Thatcher visited Merseyside and it was decided that a minister should go for a longer visit. Heseltine was already chairman of the Merseyside Partnership, set up by his predecessor Peter Shore, to channel government money into Liverpool (six other partnerships existed). Heseltine visited Liverpool accompanied by a dozen or so officials from different ministries. Timothy Raison, a junior Home Office minister, went ostensibly to check on race matters but actually to ensure that Heseltine did not interfere in police matters. Heseltine visited council estates, often accompanied by gangs of grinning children trying to be noticed on television, and his flamboyance as a self-made man went down surprisingly well in a City famous for turning out flamboyant figures in the entertainment industry. He talked to black community leaders, who complained about police bias and brutality, and he later had an awkward private meeting with the Chief constable Kenneth Oxford about the matter.
"Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome". European Journal of Endocrinology. 158 (6): 793–801. doi:10.1530/EJE-07-0857. PMID 18322300. Jensterle, Mojca; Janez, Andrej; Vrtovec, Bojan; Meden-Vrtovec, Helena; Pfeifer, Marija; Prezelj, Janez; Kocjan, Tomaz (2007). "Decreased Androgen Levels and Improved Menstrual Pattern after Angiotensin II Receptor Antagonist Telmisartan Treatment in Four Hypertensive Patients with Polycystic Ovary Syndrome: Case Series". Croatian Medical Journal. 48 (6): 864–70. doi:10.3325/cmj.2007.6.864. PMC 2213810. PMID 18074422. Silič, Anja; Janež, Andrej; Tomažič, Janez; Karner, Primož; Vidmar, Ludvik; Sharma, Prem; Matičič, Mojca (2007). "Effect of Rosiglitazone and Metformin on Insulin Resistance in Patients Infected with Human Immunodeficiency Virus Receiving Highly Active Antiretroviral Therapy Containing Protease Inhibitor: Randomized Prospective Controlled Clinical Trial". Croatian Medical Journal. 48 (6): 791–9. doi:10.3325/cmj.2007.6.791. PMC 2213797. PMID 18074413. Steiner, Charles A.; Janez, Andrej; Jensterle, Mojca; Reisinger, Katrin; Forst, Thomas; Pfützner, Andreas (2007). "Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome". Journal of Diabetes Science and Technology. 1 (2): 211–7. doi:10.1177/193229680700100212. PMC 2771474. PMID 19888409. Mlinar, B; Marc, J; Janez, A; Pfeifer, M (2007).
Initial rate experiments. When an enzyme is mixed with a large excess of the substrate, the enzyme-substrate intermediate builds up in a fast initial transient. Then the reaction achieves a steady-state kinetics in which enzyme substrate intermediates remains approximately constant over time and the reaction rate changes relatively slowly. Rates are measured for a short period after the attainment of the quasi-steady state, typically by monitoring the accumulation of product with time. Because the measurements are carried out for a very short period and because of the large excess of substrate, the approximation that the amount of free substrate is approximately equal to the amount of the initial substrate can be made. The initial rate experiment is the simplest to perform and analyze, being relatively free from complications such as back-reaction and enzyme degradation. It is therefore by far the most commonly used type of experiment in enzyme kinetics. Progress curve experiments. In these experiments, the kinetic parameters are determined from expressions for the species concentrations as a function of time. The concentration of the substrate or product is recorded in time after the initial fast transient and for a sufficiently long period to allow the reaction to approach equilibrium. Progress curve experiments were widely used in the early period of enzyme kinetics, but are less common now. Transient kinetics experiments. In these experiments, reaction behaviour is tracked during the initial fast transient as the intermediate reaches the steady-state kinetics period.
As a result, people with a history of cardiovascular disease may derive benefit from statins irrespective of their cholesterol levels (total cholesterol below 5.0 mmol/L [193 mg/dL]), and in men without cardiovascular disease, there is benefit from lowering abnormally high cholesterol levels ("primary prevention"). Primary prevention in women was originally practiced only by extension of the findings in studies on men, since, in women, none of the large statin trials conducted prior to 2007 demonstrated a significant reduction in overall mortality or in cardiovascular endpoints. Meta-analyses have demonstrated significant reductions in all-cause and cardiovascular mortality, without significant heterogeneity by sex.
Sources: en.wikipedia.org
As all except the earliest aircraft were obtained under Lend-Lease, all Mustang aircraft still on RAF charge at the end of the war were either returned to the USAAF "on paper" or retained by the RAF for scrapping. The last RAF Mustangs were retired from service in 1947.
=== Receptor ectodomain shedding === When the extracellular domain of GHR is proteolytically cleaved (see: proteolytic cleavage) from the rest of the receptor protein, the extracellular domain is released as the water-soluble, carrier protein GHBP. As the extracellular domain alone, the polypeptide consists of 246 amino acids and is roughly 60 kDA in size. This cleaving process is called “receptor ectodomain shedding. In humans and rabbits, tumor-necrosis factor alpha converting enzyme (T.A.C.E.) is postulated to play a significant role in the post-translational processing activity that sheds GHBP from GHR. Studies show that this activity primarily occurs in the liver. When growth hormone is bound to two dimerized GH receptors, the shedding activity is inhibited. This occurs because when the ligand binds to the receptors, a conformational change occurs in them that potentially blocks the proteolytic activity of T.A.C.E.
pore size distribution and surface area) can be tuned according to what is needed. Its usefulness also derives from its large micropore (and sometimes mesopore) volume and the resulting high surface area. Recent research works reported activated carbon as an effective agent to adsorb cationic species of toxic metals from multi-pollutant systems and also proposed possible adsorption mechanisms with supporting evidences.
=== Death domain === Telliez and colleagues, in a bioinformatics search for proteins possessing a death domain that resembles the one found in human receptor-interacting serine/threonine kinase 1 (RIPK1, also known as RIP1), discovered a protein and named it LRDD based on its structural characteristics. Through sequence analysis, it was discovered to contain leucine-rich repeats (LRRs) at the N-terminal region, ZU5 domains (found in ZO-1 and Unc5-like netrin receptors) in the middle section, and a death domain (DD) at the C-terminus. Additionally, a structural domain referred to as the uncharacterized protein domain in UNC5, PIDD, and ankyrins (UPA) was also identified between the ZU5 domain and the death domain (DD).
The 1st Infantry Division's 5th Battalion, 16th Infantry also played a significant role clearing the trenches and captured 160 Iraqi soldiers in the process. Once into Iraqi territory Task Force 1–41 Infantry encountered multiple Iraqi defensive positions and bunkers. These defensive positions were occupied by a brigade-sized element. Task Force 1–41 Infantry elements dismounted and prepared to engage the enemy soldiers who occupied these well-prepared and heavily fortified bunkers. The Task Force found itself engaged in six hours of combat in order to clear the extensive bunker complex. The Iraqis engaged the Task Force with small arms fire, RPGs, mortar fire, and what was left of Iraqi artillery assets. A series of battles unfolded resulting in heavy Iraqi casualties and the Iraqis being removed from their defensive positions with many becoming prisoners of war. Some escaped to be killed or captured by other coalition forces. In the process of clearing the bunkers, Task Force 1–41 captured two brigade command posts and the command post of the Iraqi 26th Infantry Division. The Task Force also captured a brigade commander, several battalion commanders, company commanders, and staff officers. As combat operations progressed Task Force 1–41 Infantry engaged at short range multiple dug in enemy tanks in ambush positions. For a few hours, bypassed Iraqi RPG-equipped anti-tank teams, T-55 tanks, and dismounted Iraqi infantry fired at passing American vehicles, only to be destroyed by other US tanks and fighting vehicles following the initial forces.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.